SCHEMBL29927600

SCHEMBL29927600

C[C@H]1CN(C(=O)OCc2ccccc2)CCN1CCC1(F)CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 1/20 0.52
PDK2 Q15119 1/20 0.52
PDK3 Q15120 1/20 0.52
PDK4 Q16654 1/20 0.52
KDM1A O60341 2/20 0.47
PARP1 P09874 1/20 0.43
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
TACR1 P25103 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CYP2C19 P33261 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
GPR119 Q8TDV5 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29927865 0.91 PDK1 (0.51) PDK1PDK2PDK3PDK4KDM1A
SCHEMBL29927665 0.90 PDK1 (0.50) PDK1PDK2PDK3PDK4KDM1A
SCHEMBL29132069 0.85 PDK1 (0.50) PDK1PDK2PDK3PDK4KDM1A
SCHEMBL30144155 0.85 PDK1 (0.52) PDK1PDK2PDK3PDK4PARP1
SCHEMBL29927746 0.84 PDK1 (0.49) PDK1PDK2PDK3PDK4KDM1A
SCHEMBL29927199 0.84 PDK1 (0.45) PDK1PDK2PDK3PDK4KDM1A
SCHEMBL29132221 0.84 EPHX2 (0.36) PDK1PDK2PDK3PDK4SMN1; SMN2
SCHEMBL29927363 0.83 PDK1 (0.50) PDK1PDK2PDK3PDK4PARP1
SCHEMBL34461278 0.81 KDM1A (0.54) KDM1AHTTSMN1; SMN2NPC1RAB9A
SCHEMBL25845757 0.81 SMN1; SMN2 (0.51) KDM1AHTTSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559506-B2 Indazole based compounds and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-02-24 US disclosed
US-20240360152-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2024-10-31 US disclosed
US-11981683-B2 Indazole based compounds and associated methods of use ARVINAS OPERATIONS, INC. (US) 2024-05-14 US disclosed
EP-4308557-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2024-01-24 EP disclosed
CN-117321046-A Indazole-based compounds and related methods of use 阿维纳斯企业公司 2023-12-29 CN disclosed
US-20230097358-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2023-03-30 US disclosed
WO-2022198112-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2022-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360152-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE LRRK2, CRBN, MDM2 PDK1 1366/4885PDK2 1007/4885PDK3 1092/4885
US-12559506-B2 Indazole based compounds and associated methods of use LRRK2, CRBN, CLK2 PDK1 2125/4885PDK2 1878/4885PDK3 1663/4885
US-11981683-B2 Indazole based compounds and associated methods of use LRRK2, CRBN, MDM2 PDK1 1366/4885PDK2 1007/4885PDK3 1092/4885
US-20230097358-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE LRRK2, CRBN, MDM2 PDK1 1366/4885PDK2 1007/4885PDK3 1092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.